Single cell sequencing has transformed our ability to discern the cellular and molecular makeup of human immune systems and tissues. The size and complexity of the data sets generated requires the application of advanced analytics and artificial intelligence to reveal the signal contained within. The marriage of scRNAseq + AI has been shown to identify rare cell populations/subtypes and provide novel insights about disease diving pathways. The ability to better understand human disease etiology has transformational impact for the biopharma industry.
In this webinar, please join the invited guest speakers as they discuss how the combination of single cell RNAseq and Artificial Intelligence can reveal causal biology and aid the understanding of disease mechanisms. The presenters will explain how the generation and analysis of this data is key to business strategy and the challenges and success they have experienced in applying these technologies together.
Thomas W. Chittenden, PhD, DPhil, PStat, Chief Data Science Officer, WuXi NextCODE
Dr. Thomas Chittenden is Chief Data Science Officer and Founding Director of the WuXi NextCODE Advanced Artificial Intelligence Research Laboratory. Dr. Chittenden is responsible for development and execution of our global AI/ML R&D strategy. This R&D initiative includes development of advanced deep learning, statistical machine learning and probabilistic programming strategies aimed at furthering scientific understanding of human disease initiation and progression, knowledge that can be directly applied in innovative products for better care and medicine in a range of disease areas.
Dr. Chittenden is an Omega Society Fellow with over 25 years of experimental and theoretical research experience. The principal focus of Dr. Chittenden’s work is the development and application of integrated systems biology models to investigate evolutionary factors of human disease. He is currently applying quantum information theory to decipher an elemental molecular code regulating patterns of biological complexity.
Dr. Chittenden’s work has been published in top-tier scientific journals, including featured articles in Nature and Science. In 2019, Dr. Chittenden was named among the top 100 AI Leaders in Drug Discovery and Advanced Healthcare. He is regarded as one of the world’s leading authorities on AI and causal statistical machine learning in precision medicine.Message Presenter
Gregory Ryslik, PhD, FCAS, MAAA, Chief Data Officer, Celsius Therapeutics
Gregory Ryslik is a statistician, data scientist and artificial intelligence researcher with experience building and leading data initiatives in companies ranging across the biotech, autotech, healthtech and fintech domains. Prior to Celsius Therapeutics, he was vice president of data science at Mindstrong Health, a healthcare company transforming mental health treatment through measurement science and artificial intelligence. Previously, Greg was the senior director and head of data science at Faraday Future, an electric vehicle startup in Los Angeles as well as the leader of the service data science group at Tesla Motors in Palo Alto. Earlier in his career, he performed machine learning research and nonclinical biostatistics research at Genentech.Message Presenter
Robert Deans, PhD, CSO, Synthego
Dr. Deans is CSO at Synthego, a genome engineering company pushing automation and machine learning towards a new era of cell and gene therapeutics. Prior to Synthego, Dr. Deans was Chief of Innovation at BlueRock Therapeutics, a biotechnology company creating allogeneic cell therapeutics by harnessing pluripotent stem cell biology and gene editing tools. Prior to BlueRock, Dr. Deans was CSO at Rubius Therapeutics developing a platform of novel enucleated cell therapeutics based on genetic engineering and expansion of hematopoietic progenitors to mature reticulocytes. Dr. Deans has more than 25 years of experience in adult stem cell therapeutics which includes stem cells from bone marrow including both hematopoietic gene therapies as well as mesenchymal stromal cell (MSC) populations.Message Presenter
Who Should Attend?
- Head, Translational Medicine
- Director Translational Biology
- VP Translational Biology
- R&D Dir., Platform
- Senior or Principal Researcher
- Senior or Principal Investigator
- Senior or Principal Scientist
- Head of Discovery Sciences
- Senior Director, Early Development and Translational Sciences
- Executive Vice President, Research and Development
What You Will Learn
In this webinar, attendees will:
- Gain an understanding of how single cell RNA sequencing can offer a unique lens into a cellular / tissue microenvironment
- Gain an understanding of how AI can reveal clusters in scRNA data
- Understand how biopharma is applying SC-AI today
- Learn about some recent discoveries fueled by SC-AI
- The challenges of applying AI to SC data and why these are complimentary technologies
WuXi NextCODE is a global genomic data and insights company that serves the world’s leading biopharma and medical research centers. WuXi NextCODE enables the use of genomic data in target discovery, validation /invalidation, biomarker identification / validation and clinical trial design. Core capabilities span the sourcing of clinical omics, data generation (WES, WGS, RNAseq), and secure management and analysis of data, from single cell to population scale. WuXi NextCODE works collaboratively with clients, providing a world class team with deep genomics, biology and artificial intelligence domain expertise to accelerate time to insight. Our US lab, in the heart of Boston’s biotech provides Single Cell Sequencing services to enable deeper understanding of disease and cellular biology.